Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
Long-Term Data in Patients Receiving Every-Four-Week Subcutaneous SIMPONI Presented at 2009 EULAR Annual Congress
COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) inject...
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Improvements in Systolic Blood Pressure and Triglycerides Also Observed
NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) today announced long-term, interim results from the ...
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
First-of-its-Kind Study Demonstrates REMICADE More Likely to Maintain Steroid-Free Remission in Patients Naive to Immunomodulators and BiologicTherapy
CHICAGO, June 2 /PRNewswire/ -- New long-term findings from the Phase 3b study of patients with moderately to severely active Crohn's disease...
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data -
CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produ...
Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN )
today released updated results from the ongoing, open-label extension study of
the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult
patients with chronic immune thrombocytopenic purpura (ITP). Chronic IT...
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting
Pivotal Phase III studies ongoing in treatment naive patients and those
who failed prior treatment
SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today reported that a planned...
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
- Higher Sustained
Virological Response Rates Recognized as Marker of
Treatment Success -
SAN FRANCISCO, Calif., Nov. 1 /PRNewswire/ -- A new,
independently-conducted study being presented at the 59th Annual Meeting of
the American Association for the Study of Liver Diseases (AASLD) shows th...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
CIMZIA(R) Data Shows Long-term Improvements in Productivity, Quality of Life and Lessened Fatigue According to Studies Presented at American College of Rheumatology (ACR) Annual Scientific Meeting
SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced
today results from se...
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Data Analysis of Up to Four Years of Treatment Presented at ICAAC/IDSA
2008 Annual Meeting
WASHINGTON, Oct. 26 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today reported a data analysis showing that
vicriviroc, its investigational CCR5 receptor antagonist, demonstrate...
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
'New Class' of Stent with Polyzene(R)-F Surface Treatment Maximizes
Endothelialization; Reduces Restenosis, Thrombogenicity, Need for Long-Term
Dual Antiplatelet Therapy
WASHINGTON, Oct. 13 /PRNewswire/ -- Clinical investigators at today's
"Innovative Devices and Futuristic Therapies" sessio...
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials -
PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc.
(Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of
obesity and other ce...
Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
Results published in New England Journal of Medicine reaffirm
well-established efficacy and long-term safety profile of SPIRIVA(R)
RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNewswire/ -- Results of the
UPLIFT (Understanding Potential Long-term Impacts on Function with
Critical Pharmaceuticals Enter Sustained Release hGH Arena
Preclinical Results of New Somatropin Formulation Demonstrate Advantages Over Existing Once-Daily Product
NOTTINGHAM, England, October 1 /PRNewswire/ -- Critical
Pharmaceuticals, the Nottingham, UK-based speciality pharmaceuticals
company, today announced that the successful...
New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
Earlier treatment initiation and longer exposure to Betaseron was
associated with improved long-term outcomes in multiple sclerosis
MONTREAL, Sept. 19 /PRNewswire/ -- Data presented at the World Congress
on Treatment and Research in Multiple Sclerosis (WCTRIMS) demonstrated that
Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
WELLESLEY HILLS, Mass., Aug. 25 /PRNewswire/ -- Joseph F. Finn, Jr.,
C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for
the benefit of creditors, announced today that all pharmaceutical
intellectual property will be sold at a sealed bid auction on October 10,
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
74 percent of patients achieved SVR 12 with 48-week boceprevir-based combination therapy High SVR 24 rate also reported for 28-week boceprevir arm
KENILWORTH, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today reported top-li...
FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
Data Provides Further Information on AVANDIA as a Safe and Effective Treatment Option for Appropriate Type 2 Diabetes Patients
PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:
GSK) announces today that the U.S. Food and Drug Administration (FDA)
updated the prescr...
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
EORTC 18991 Phase III Study Results Published in The Lancet
KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today,
Schering-Plough (NYSE: SGP ) and the EORTC announced that long-term
treatment with pegylated interferon alfa-2b in stage III melanoma patients
had a significant and sus...
Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Corifollitropin alfa meets primary endpoints in ENGAGE Trial
KENILWORTH, N.J., July 8 /PRNewswire-FirstCall/ -- Schering-Plough
Corp., (NYSE: SGP ) announced today that corifollitropin alfa, its
follicle stimulant (SFS) met its primary endpoints
in the Phase III ...
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved Glucose Control in Patients Switching from Exenatide Taken Twice a Day
SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc.
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
Believed by experts to be important for cervical cancer prevention
GRAZ, Austria, May 14 /PRNewswire-FirstCall/ -- New data from an
extended follow-up study show that GlaxoSmithKline (NYSE: GSK ) cervical
cancer candidate vaccine, CERVARIX(R) generates sustained
high levels of
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
- Phase II study extension shows 68-73% of patients with multiple sclerosis
remained relapse-free after three years of treatment with oral FTY720
- New data demonstrate 89% of patients free from active brain lesions - the injury caused by MS - three years after starting treatment
- MS, ...
Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,
Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a
pharmaceutical company in the People's Republic of China ("PRC"), today
announced that it has achieved significant milestones in the development of
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
VIENNA, Austria, Sept. 3 /PRNewswire/ -- Clinical investigators at the
European Society of Cardiology Congress 2007 (ESC Congress 2007) reported
today that the CYPHER(R) Sirolimus-eluting Coronary Stent continued to
provide clinical benefits compared to a bare metal stent in the E-SIRIUS
New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
CAIRNS, Australia, Aug. 31 /PRNewswire/ -- What and When Data from a six-month study of ramelteon will be presented in poster
format at worldsleep07: The 5th World Congress of the World Federation of
Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia
September 2-6, 2...
Seroquel Sustained Release Schizophrenia Data Presented at ECP
Congress in Madrid
LONDON, March 18, 2007-AstraZeneca today announced clinical
trial data for Seroquel sustained
release formulation (quetiapine
release), at the European Congress of Psychiatry
(ECP) in Madrid. The data demonstrated that the SEROQUEL®
sustained release formulation (quetiapine ...
Copaxone Treatment over Two Years after Short Term Induction with
Mitoxantrone Provided Sustained Benefits to Active
Relapsing-Remitting Multiple Sclerosis Patients
KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data have
demonstrated that relapsing-remitting multiple sclerosis (RRMS)
patients treated with COPAXONE(R) (glatiramer acetate injection)
following brief immunosuppression with mitoxantrone experienced a
90 percent reduction in magnetic resonanc...
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III
Melanoma Demonstrated Significant and Sustained Impact on
-- EORTC 18991 Phase III Study Results Presented At ASCO --
CHICAGO – June 2, 2007 – Long-term treatment with
pegylated interferon alfa-2b in stage III melanoma had a
significant and sustained
impact on relapse-free survival (RFS),
according to the results of the largest adjuvant tri...
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
...hat uses a tiny silicone cup filled with any drug and sealed to the outer surface (episclera) of the eyeball may offer a more effective method for the sustained
delivery of medicines for retinal and vitreous diseases, according to a new report by A. Linn Murphree, M.D, director of the Retinoblastoma Program in...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...y, at the American Diabetes Association (ADA) scientific sessions.
Isis presented new preclinical data on ISIS-SGLT2Rx showing robust and sustained
reduction in SGLT2 levels that resulted in a significant reduction in blood glucose levels in multiple animal species.
Isis and its collaborator...
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
...d improvements in two key markers of liver injury, with mean AST and ALT levels decreasing to below the upper limit of normal. These improvements were sustained
for up to 6 days post-dosing, and most levels returned to baseline 14 days post-treatment.
"We have made great progress in our HCV discovery ...
Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
... product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained
weight loss. Further information about the Company can be found at www.orexigen.com .
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
...f therapy and was maintained. The most frequent adverse events were expected based on TASKi1 and appear to be manageable. The significant, early and sustained
efficacy, combined with a good safety profile, supports Rigel's plans to conduct corporate partnership discussions with respect to R788 and initiate a...
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
... the end of study
About Cervarix (R)
Cervarix (R) was specifically designed with a novel adjuvant, AS04, to deliver high and sustained
levels of antibodies aimed at providing long-term protection against HPV 16 and 18, the most common cervical cancer-causing HPV types. It has been sho...
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
...% (glargine vs NPH) diabetes duration 11 years, and about 70% of the population was already treated with insulin prior to study entry.
glycaemic control was observed in both the glargine and NPH treatment groups. Despite a slightly greater severity of diabetic retinopathy for the glar...
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value
...ose programs has been made, Eisai announces the status as follows:
Eisai has completed a Phase III study of Aricept 23 mg sustained
release (SR) in patients with moderate to severe Alzheimer's disease. Arice...
Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
...inical trial of its lead development compound VA106483 for
nocturia. The trial showed that oral VA106483 was successful in producing a
predictable and sustained
anti-diuretic effect in patients, as determined by
increased osmolality and decreased urine output. The study also found that
VA106483 was generally w...
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
...pest, demonstrated that add-on treatment with the novel,
once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted
in a marked and sustained
decrease in seizure frequency over the long-term(1).
Results from the one-year extension of a pivotal Eslicarbazepine Acetate
phase III study w...
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
...9 towards the end of this year."
Dr Chris Blackwell, Chief Executive of Vectura, added: "The Phase II
studies demonstrated that NVA237 provides sustained
in patients with moderate to severe COPD. As it now enters the final stage of
clinical development before market, confidence i...
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
...l cardiovascular safety trial that satisfies the December 2008 FDA Guidance.
"Takeda will continue to promote key initiatives in order to realize sustained
growth from a medium- to long-term perspective," said Takeda President & CEO, Yasuchika Hasegawa.
About Takeda Pharmaceutical Company Limit...